Ampreloxetine hydrochloride is under clinical development by Theravance Biopharma and currently in Phase III for Orthostatic Hypotension. According to GlobalData, Phase III drugs for Orthostatic Hypotension have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ampreloxetine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ampreloxetine hydrochloride overview

Ampreloxetine HCL (TD-9855) was under development for the treatment of multiple system atrophy (MSA) patients suffering with neurogenic orthostatic hypotension (NOH), attention deficit hyperactivity disorder (ADHD) and fibromyalgia. The drug candidate is administered orally as a tablet and is a new molecular entity. It acts by targeting serotonin and norepinephrine reuptake.

Theravance Biopharma overview

Theravance Biopharma is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis and concurrent bacteremia. Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future payments made to Innoviva, Inc from Glaxo Group Limited or one of its affiliates. The company has subsidiaries in the US, Ireland and the UK. Theravance Biopharma is headquartered in San Francisco, California, the US.

For a complete picture of Ampreloxetine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.